Baird Maintains Bullish View on Karyopharm Therapeutics (KPTI) Following Positive STORM Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma
September 6, 2016 7:00 AM EDT
- Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refractory Disease -
- Expanding Phase 2b STORM Study to Include Approximately 120 Additional Patients with Penta-Refractory Myeloma to Support Seeking Accelerated Approval -
- Plan to Initiate Pivotal Randomized Phase 3 BOSTON Study in early 2017 to Evaluate Selinexor in Combination with Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Previously Treated Myeloma Patients -
- Management to Host Conference Call Today at... More
